Abstract
BackgroundCoronary artery disease (CAD) is considered as a multi-faceted chronic inflammatory disease involving reduced blood supply to the myocardium as a result of accumulating lipids in the atrial walls. Visceral adiposity with disrupted release of adipokines play a key role in its pathogenesis. Asprosin is a newly identified fasting-induced glucogenic adipokine that has been related with metabolic disorders such as type II diabetes mellitus and polycystic ovary syndrome. The preset study sought to assess circulating asprosin in context of CAD.MethodsIn this study, serum levels of asprosin were determined in 88 CAD patients and 88 non-CAD healthy controls. Serum IL-6, TNF-α, asprosin and adiponectin were assessed using ELISA kits.Results: Serum asprosin was found to be higher in CAD patients when compared to non-CAD subjects (7.84 ± 2.08 versus 5.02 ± 1.29 μg/mL, p < 0.001). Similarly, serum TNF-α, and IL-6 elevated in CAD group significantly (p < 0.001). However, circulating adiponectin diminished in CAD group when compared with non-CAD subjects (p < 0.001). Moreover, serum asprosin levels directly correlated with BMI, FBG, HOMA-IR, TG and TC. Logistic regression analyses showed that asprosin levels were associated with increased risk of developing CAD (odds ratio: 3.01, 95% CI: 2.16, 4.20 and p < 0.001), after adjusting for potential confounders (age, sex and BMI).ConclusionsThe present study findings suggested a possible relation of serum asprosin with the pathogenesis of CAD, in particular through insulin resistance and dyslipidemia.
Highlights
Coronary artery disease (CAD), affects 1655 per 100,000 worldwide, and is expected to exceed 1845 by 2030
The levels of TG elevated (p < 0.001) and HDL-C decreased in patient group compared to non-CAD subjects (p = 0.021), while TC and LDL-C indicated no considerable change between the groups
Serum levels ALT and AST were found to be higher in CAD patients when compared to non-CAD group (p < 0.05)
Summary
Coronary artery disease (CAD), affects 1655 per 100,000 worldwide, and is expected to exceed 1845 by 2030. It is the main cause of death globally, with 9 million deaths annually [1]. CAD continues to exert a global economic burden [2]. It is a chronic inflammatory disease state, with a concomitant accumulation of cholesterol and activation of both innate and adaptive immune responses, and eventually leading to atherosclerosis [3]. Coronary artery disease (CAD) is considered as a multi-faceted chronic inflammatory disease involving reduced blood supply to the myocardium as a result of accumulating lipids in the atrial walls. The preset study sought to assess circulating asprosin in context of CAD
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
